New therapeutic approaches based on modulation of the intestinal microbiota to correct dysbiosis in patients with type 2 diabetes.

##plugins.themes.academic_pro.article.sidebar##

Published Jan 22, 2026
https://doi.org/10.62438/tunismed.v103i11.6101
Download
PDF
Vol. 103 No. 11 (2025): Tunis Med Nov 2025

##plugins.themes.academic_pro.article.main##

Hanane Lerhzouli
Team of Nutritional Sciences, Food and Health, Laboratory of Biology and Health, Department of Biology, Faculty of Sciences, University Ibn Tofail, Kenitra, Morocco
Btihaj AL Ibrahmi
Team of Nutritional Sciences, Food and Health, Laboratory of Biology and Health, Department of Biology, Faculty of Sciences, University Ibn Tofail, Kenitra, Morocco
Soad khal-layoun
Team of Nutritional Sciences, Food and Health, Laboratory of Biology and Health, Department of Biology, Faculty of Sciences, University Ibn Tofail, Kenitra, Morocco
Abdellatif Bour
Team of Nutritional Sciences, Food and Health, Laboratory of Biology and Health, Department of Biology, Faculty of Sciences, University Ibn Tofail, Kenitra, Morocco

Abstract

Type 2 diabetes is a chronic disease characterized by insulin resistance and reduced insulin production in pancreatic cells. Conventional treatment of type 2 diabetes relies on hypoglycemic drugs, physical activity and a balanced low-carbohydrate diet, but with technological advances in metagenomics and metabolomics researchers have developed new therapeutic approaches aimed to modulate, the gut microbiota to correct the dysbiosis confirmed in people with type 2 diabetes. This literature review provides an update on therapies aimed to modulate the gut microbiota to correct dysbiosis in type 2 diabetics and summarizes the latest advances in this field.

Keywords:

type 2 diabetes, gut microbiota, dysbiosis, Mediterranean diet, probiotic and prebiotics supplementation

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. World Health Organizations, https://www.who.int/fr/news-room/fact-sheets/detail/diabetes.2023
  2. Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs. 2002 Jan;16(2):17-23.
  3. Schlienger JL. Type 2 diabetes complications.Presse Med. 2013;42(5):839-48.
  4. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239-51.
  5. Landman C, Quévrain E. Gut microbiota: Description, role and pathophysiologic implications. Rev Med Interne. 2016;37(6):418-423.
  6. Barbut F, Joly F. Le microbiote intestinal: équilibre et dysbiose. Hépato-Gastro & Oncologie Digestive.2010, 17(6), 511-20.
  7. Filleron A, Jumas-Bilak E. Implantation du microbiote intestinal chez l’enfant: ontogenèse d’une niche écologique. Revue Francophone des Laboratoires, 2015(469) : 27-35.
  8. Dominguez-Bello MG, Costello EK, Contreras M,Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971-75.
  9. Deschasaux M, Zwinderman K, Nieuwdorp M. How the gut microbiota composition relates to the ethnic background. Med Sci (Paris). 2019;35(5):401-4.
  10. Corthier G. Le microbiote: un monde polymorphe aux fonctions multiples. Cahiers de Nutrition et de Diététique. 2007,42, 21.
  11. Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016;375(24):2369-79.
  12. Marteau P, Doré J. Le microbiote intestinal. EMC-Gastro-entérologie.2017 ; 12, 1-8.
  13. Polidori I, Marullo L, Ialongo C, Tomassetti F, Colombo R, di Gaudio F et al. Characterization of Gut Microbiota Composition in Type 2 Diabetes Patients: A Population-Based Study. Int J Environ Res Public Health. 2022;19(23):15913.
  14. Umirah F, Neoh CF, Ramasamy K, Lim SM. Differential gut microbiota composition between type 2 diabetes mellitus patients and healthy controls: A systematic review. Diabetes Res Clin Pract. 2021;173:108689.
  15. Zhang L, Chu J, Hao W, Li H, Yang C, Yang J et al. Gut Microbiota and Type 2 Diabetes Mellitus: Association, Mechanism, and Translational Applications. Mediators Inflamm. 2021;2021:5110276.
  16. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590.
  17. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085.
  18. Merra G, Noce A, Marrone G, Cintoni M, Tarsitano MG, Capacci A, et al. Influence of Mediterranean Diet on Human Gut Microbiota. Nutrients. 2020;13(1):7.
  19. Naureen Z, Bonetti G, Medori MC, Aquilanti B, Velluti V, Matera G, et al. Foods of the Mediterranean diet: lacto-fermented food, the food pyramid and food combinations. J Prev Med Hyg. 2022;63(2 Suppl 3):E28-E35.
  20. Serra-Majem L, Bach-Faig A, Raidó-Quintana B. Nutritional and cultural aspects of the Mediterranean diet. Int J Vitam Nutr Res. 2012;82(3):157-62.
  21. Ozsoy S, Sultanoglu N, Sanlidag T. The role of Mediterranean diet and gut microbiota in type-2 diabetes mellitus associated with obesity (diabesity). J Prev Med Hyg. 2022;63(2 Suppl 3):E87-E92.
  22. Ismael S, Silvestre MP, Vasques M, Araújo JR, Morais J, Duarte MI, et al. A Pilot Study on the Metabolic Impact of Mediterranean Diet in Type 2 Diabetes: Is Gut Microbiota the Key?. Nutrients. 2021;13(4):1228.
  23. Galié S, García-Gavilán J, Papandreou C, Arcelin P, Palau-Galindo A, Rabassa A, et al. Effects of Mediterranean Diet on plasma metabolites and their relationship with insulin resistance and gut microbiota composition in a crossover randomized clinical trial. Clin Nutr. 2021;40(6):3798-806.
  24. Deledda A, Palmas V, Heidrich V, Fosci M, Lombardo M, Cambarau G, et al. Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity. Metabolites. 2022;12(11):1092.
  25. Boclé JC, Champ M, Berta JL. Les fibres alimentaires: déterminants physico-chimiques, définition, aspects analytiques et physiologiques. Cahiers de Nutrition et de Diététique. 2005;40(1) : 15-21.
  26. Mosoni P. Dégradation des fibres alimentaires par le microbiote colique de l’Homme. Innovations Agronomiques. 2014; 36 : 83-96.
  27. Misquith A, Rangareddy H, Ashakiran S, Shetty A. From plant to plate: understanding the benefits of dietary fibres on health. 2023.
  28. Fu J, Zheng Y, Gao Y, Xu W. Dietary Fiber Intake and Gut Microbiota in Human Health. Microorganisms. 2022;10(12):2507.
  29. Dhingra D, Michael M, Rajput H, Patil RT. Dietary fibre in foods: a review. J Food Sci Technol. 2012;49(3):255-66.
  30. Markowiak P, Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017;9(9):1021.
  31. Gómez B, Gullón B, Remoroza C, Schols HA, Parajó JC, Alonso JL. Purification, characterization, and prebiotic properties of pectic oligosaccharides from orange peel wastes. J Agric Food Chem. 2014;62(40):9769-82.
  32. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics--approaching a definition. Am J Clin Nutr. 2001;73(2 Suppl):361S-4S.
  33. Cronin P, Joyce SA, O'Toole PW, O'Connor EM. Dietary Fibre Modulates the Gut Microbiota. Nutrients. 2021;13(5):1655.
  34. Yang Q, Liang Q, Balakrishnan B, Belobrajdic DP, Feng QJ, Zhang W. Role of Dietary Nutrients in the Modulation of Gut Microbiota: A Narrative Review. Nutrients. 2020;12(2):381.
  35. Biswas V, Praveen A, Marisetti AL,Sharma A, Kumar V, Sahu SK, et al. A Mechanistic Overview on Impact of Dietary Fibres on Gut Microbiota and Its Association with Colon Cancer. Dietetics.2022; 1(3), 182-202.
  36. Ojo O, Feng QQ, Ojo OO, Wang XH. The Role of Dietary Fibre in Modulating Gut Microbiota Dysbiosis in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Nutrients. 2020;12(11):3239.
  37. Chen L, Liu B, Ren L,Du H, Fei C, Qian C, et al. High-fiber diet ameliorates gut microbiota, serum metabolism and emotional mood in type 2 diabetes patients. Front Cell Infect Microbiol. 2023;13:1069954.
  38. Birkeland E, Gharagozlian S, Birkeland KI, Valeur J, Måge I, Rud I, et al. Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial. Eur J Nutr. 2020;59(7):3325-38.
  39. Frias JP, Lee ML, Carter MM, Ebel ER, Lai RH, Rikse L, et al. A microbiome-targeting fibre-enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab. 2023;25(5):1203-12.
  40. Wang Z, Peters BA, Yu B, Grove ML, Wang T, Xue X, et al. Gut Microbiota and Blood Metabolites Related to Fiber Intake and Type 2 Diabetes. Circ Res. 2024;134(7):842-54.
  41. Food and Agriculture Organization of the United Nations and World Health Organizations. Regulatory and clinical aspects of dairy probiotics. 2001.
  42. Cardinali N, Bauman C, Rodriguez Ayala F, Grau R. Two cases of type 2 diabetes mellitus successfully treated with probiotics. Clin Case Rep. 2020;8(12):3120-5.
  43. Li BY, Xu XY, Gan RY, Sun QC, Meng JM, Shang A, et al. Targeting Gut Microbiota for the Prevention and Management of Diabetes Mellitus by Dietary Natural Products. Foods. 2019;8(10):440.
  44. J Jeon J, Jang J, Park K. Effects of Consuming Calcium-Rich Foods on the Incidence of Type 2 Diabetes Mellitus. Nutrients. 2018;11(1):31.
  45. Liu S, Choi HK, Ford E, Song Y, Klevak A, Buring JE, et al. A prospective study of dairy intake and the risk of type 2 diabetes in women. Diabetes Care. 2006;29(7):1579-1584.
  46. Tonucci LB, Olbrich Dos Santos KM, Licursi de Oliveira L, Rocha Ribeiro SM, Duarte Martino HS. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin Nutr. 2017;36(1):85-92.
  47. Hsieh MC, Tsai WH, Jheng YP, Su SL, Wang SY, Lin CC, et al. The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial. Sci Rep. 2018;8(1):16791.
  48. Sato J, Kanazawa A, Azuma K,Ikeda F, Goto H, Komiya K, et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study. Sci Rep. 2017;7(1):12115.
  49. Ziegler MC, Garbim Junior EE, Jahnke VS, Lisbôa Moura JG, Brasil CS, Schimitt da Cunha PH, et al. Impact of probiotic supplementation in a patient with type 2 diabetes on glycemic and lipid profile. Clin Nutr ESPEN. 2022;49:264-9.
  50. Chen Y, Shen X, Ma T, Yu X, Kwok LY, Li Y, et al. Adjunctive Probio-X Treatment Enhances the Therapeutic Effect of a Conventional Drug in Managing Type 2 Diabetes Mellitus by Promoting Short-Chain Fatty Acid-Producing Bacteria and Bile Acid Pathways. mSystems. 2023;8(1):e0130022.
  51. Ziegler MC, Garbim Junior EE, Jahnke VS,Lisbôa Moura JG, Brasil CS, Schimitt da Cunha PH, et al. Impact of probiotic supplementation in a patient with type 2 diabetes on glycemic and lipid profile. Clin Nutr ESPEN. 2022;49:264-9.
  52. Toejing P, Khampithum N, Sirilun S, Chaiyasut C, Lailerd N. Influence of Lactobacillus paracasei HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial. Foods. 2021;10(7):1455.
  53. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-14.
  54. Salgaço MK, Oliveira LGS, Costa GN, Bianchi F, Sivieri K. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. Appl Microbiol Biotechnol. 2019;103(23-24):9229-38.
  55. Dahiya DK, Renuka, Puniya M,Shandilya UK, Dhewa T, Kumar N, et al. Gut Microbiota Modulation and Its Relationship with Obesity Using Prebiotic Fibers and Probiotics: A Review. Front Microbiol. 2017;8:563.
  56. Bianchi F, Duque ALRF, Saad SMI, Sivieri K. Gut microbiome approaches to treat obesity in humans. Appl Microbiol Biotechnol. 2019;103(3):1081-94.
  57. Balakumar M, Prabhu D, Sathishkumar C,Prabu P, Rokana N, Kumar R, et al. Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice. Eur J Nutr. 2018;57(1):279-95.
  58. Lim SM, Jeong JJ, Woo KH, Han MJ, Kim DH. Lactobacillus sakei OK67 ameliorates high-fat diet-induced blood glucose intolerance and obesity in mice by inhibiting gut microbiota lipopolysaccharide production and inducing colon tight junction protein expression. Nutr Res. 2016;36(4):337-48.
  59. Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak MY. Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. Eur J Nutr. 2017;56(4):1535-50.
  60. O'Connor S, Chouinard-Castonguay S, Gagnon C, Rudkowska I. Prebiotics in the management of components of the metabolic syndrome. Maturitas. 2017;104:11-8.
  61. Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017;46(1):171-85.
  62. Oprita R, Bratu M, Oprita B, Diaconescu B. Fecal transplantation - the new, inexpensive, safe, and rapidly effective approach in the treatment of gastrointestinal tract diseases. J Med Life. 2016;9(2):160-2.
  63. Fuhri Snethlage CM, Nieuwdorp M, Hanssen NMJ. Faecal microbiota transplantation in endocrine diseases and obesity. Best Pract Res Clin Endocrinol Metab. 2021;35(3):101483.
  64. Oprita R, Bratu M, Oprita B, Diaconescu B. Fecal transplantation - the new, inexpensive, safe, and rapidly effective approach in the treatment of gastrointestinal tract diseases. J Med Life. 2016;9(2):160-2.
  65. Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017;46(1):171-85.
  66. Al-Ali D, Ahmed A, Shafiq A,McVeigh C, Chaari A, Zakaria D, et al. Fecal microbiota transplants: A review of emerging clinical data on applications, efficacy, and risks (2015-2020). Qatar Med J. 2021;2021(1):5.
  67. Zhang F, Cui B, He X,Nie Y, Wu K, Fan D, et al. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018;9(5):462-73.
  68. Antushevich H. Fecal microbiota transplantation in disease therapy. Clin Chim Acta. 2020;503:90-8.
  69. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013;29(1):79-84.
  70. Cañar KA, Recalde-Navarrete R. Fecal microbiota transplant as a new therapeutic in the management of type 2 Diabetes Mellitus.2025.
  71. Chen L, Guo L, Feng S, Wang C, Cui Z, Wang S, et al. Fecal microbiota transplantation ameliorates type 2 diabetes via metabolic remodeling of the gut microbiota in db/db mice. BMJ Open Diabetes Res Care. 2023;11(3):e003282.
  72. Zhang PP, Li LL, Han X,Li QW, Zhang XH, Liu JJ, et al. Fecal microbiota transplantation improves metabolism and gut microbiome composition in db/db mice. Acta Pharmacol Sin. 2020;41(5):678-85.
  73. Han X, Wang Y, Zhang P, Zhu M, Li L, Mao X, et al. Kazak faecal microbiota transplantation induces short-chain fatty acids that promote glucagon-like peptide-1 secretion by regulating gut microbiota in db/db mice. Pharm Biol. 2021;59(1):1077-87.
  74. Wu Z, Zhang B, Chen F, Xia R, Zhu D, Chen B, et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. Front Cell Infect Microbiol. 2023;12:1089991.
  75. Wang H, Lu Y, Yan Y,Tian S, Zheng D, Leng D, et al. Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets. Front Cell Infect Microbiol. 2020;9:455.
  76. Gómez-Pérez AM, Muñoz-Garach A, Lasserrot-Cuadrado A, Moreno-Indias I, Tinahones FJ. Microbiota Transplantation in Individuals with Type 2 Diabetes and a High Degree of Insulin Resistance. Nutrients. 2024;16(20):3491.
  77. Toca MDC, Burgos F, Tabacco O, Vinderola G. Postbiotics: A new member in the biotics family. Arch Argent Pediatr. 2024 Oct 1;122(5):e202310168.
  78. AguilarR-Toala, JE, Arioli S, Behare P, et al. Postbiotics—When simplification fails to clarify. Nature Reviews Gastroenterology & Hepatology. 2021; 18(11): 825-826.
  79. Fang H, Rodrigues E-Lacerda R, Barra NG, Kukje Zada D, Robin N, Mehra A, Schertzer JD. Postbiotic Impact on Host Metabolism and Immunity Provides Therapeutic Potential in Metabolic Disease. Endocr Rev. 2025 Jan 10;46(1):60-79.
  80. Vinderola G, Sanders ME, Salminen S. The Concept of Postbiotics. Foods. 2022 Apr 8;11(8):1077.
  81. Chen K, Wang H, Yang X, Tang C, Hu G, Gao Z. Targeting gut microbiota as a therapeutic target in T2DM: A review of multi-target interactions of probiotics, prebiotics, postbiotics, and synbiotics with the intestinal barrier. Pharmacol Res. 2024 Dec;210:107483.
  82. Liu L, Chen Y, Wu Q, Shu A, Sun J. Sodium Butyrate Attenuated Diabetes-Induced Intestinal Inflammation by Modulating Gut Microbiota. Evid Based Complement Alternat Med. 2022 Aug 22;2022:4646245.
  83. Nam Y, Yoon S, Baek J, Kim JH, Park M, Hwang K, Kim W. Heat-Killed Lactiplantibacillus plantarum LRCC5314 Mitigates the Effects of Stress-Related Type 2 Diabetes in Mice via Gut Microbiome Modulation. J Microbiol Biotechnol. 2022 Mar 28;32(3):324-332.
  84. Arellano-García LI, Portillo MP, Martínez JA, Courtois A, Milton-Laskibar I. Postbiotics for the management of obesity, insulin resistance/type 2 diabetes and NAFLD. Beyond microbial viability. Crit Rev Food Sci Nutr. 2024 Dec 7:1-24.
  85. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-46.
  86. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007 Jul;56(7):1761-72.
  87. Blüher M, Engeli S, Klöting N, Berndt J, Fasshauer M, Bátkai S, Pacher P, Schön MR, Jordan J, Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006 Nov;55(11):3053-60.
  88. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005 Oct;54(10):2838-43.
  89. Lambert DM, Muccioli GG. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):735-44.
  90. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, Piscitelli F, Westerbacka J, Soro-Paavonen A, Matias I, Van Gaal L, Taskinen MR. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol. 2009 Nov;161(5):715-22.
  91. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 Apr 16-22;365(9468):1389-97.
  92. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring). 2009 Aug;17(8):1641-5.
  93. Kunos G, Tam J. The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol. 2011 Aug;163(7):1423-31.
  94. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007 Jul;56(7):1761-72.
  95. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther. 2011 May;130(2):202-12.
  96. Delzenne NM, Neyrinck AM, Bäckhed F, Cani PD. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol. 2011 Aug 9;7(11):639-46.
  97. Muccioli GG, Naslain D, Bäckhed F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010 Jul;6:392.
  98. André A, Gonthier MP. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol. 2010 Nov;42(11):1788-801.
  99. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, Di Marzo V. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring). 2008 Mar;16(3):553-65.
  100. Song D, Bandsma RH, Xiao C, Xi L, Shao W, Jin T, Lewis GF. Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice. Diabetologia. 2011 May;54(5):1181-9.
  101. Geurts L, Muccioli GG, Delzenne NM, Cani PD. Chronic endocannabinoid system stimulation induces muscle macrophage and lipid accumulation in type 2 diabetic mice independently of metabolic endotoxaemia. PLoS One. 2013;8(2):e55963.
  102. Jan T, Negi R, Sharma B, Kumar S, Singh S, Rai AK, Shreaz S, Rustagi S, Chaudhary N, Kaur T, Kour D, Sheikh MA, Kumar K, Yadav AN, Ahmed N. Next generation probiotics for human health: An emerging perspective. Heliyon. 2024 Aug 12;10(16):e35980.
  103. O'Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017 Apr 25;2:17057.
  104. Yoha KS, Nida S, Dutta S, Moses JA, Anandharamakrishnan C. Targeted Delivery of Probiotics: Perspectives on Research and Commercialization. Probiotics Antimicrob Proteins. 2022 Feb;14(1):15-48.
  105. Mugwanda K, Hamese S, Van Zyl WF, Prinsloo E, Du Plessis M, Dicks LMT, Thimiri Govinda Raj DB. Recent advances in genetic tools for engineering probiotic lactic acid bacteria. Biosci Rep. 2023 Jan 31;43(1):BSR20211299.
  106. Cheng HL, Yen GC, Huang SC, Chen SC, Hsu CL. The next generation beneficial actions of novel probiotics as potential therapeutic targets and prediction tool for metabolic diseases. J Food Drug Anal. 2022 Mar 15;30(1):1-10.
  107. Abouelela ME, Helmy YA. Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives. Microorganisms. 2024 Feb 20;12(3):430.
  108. Hao J, Zhang Y, Wu T, Liu R, Sui W, Zhu J, Fang S, Geng J, Zhang M. The antidiabetic effects of Bifidobacterium longum subsp. longum BL21 through regulating gut microbiota structure in type 2 diabetic mice. Food Funct. 2022 Oct 3;13(19):9947-9958.
  109. Jian H, Liu Y, Wang X, Dong X, Zou X. Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes? Int J Mol Sci. 2023 Feb 15;24(4):3900.
  110. Bui TPN, de Vos WM. Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases. Best Pract Res Clin Endocrinol Metab. 2021 May;35(3):101504.
  111. Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):625-637.
  112. Naureen Z, Dautaj A, Anpilogov K, Camilleri G, Dhuli K, Tanzi B, Maltese PE, Cristofoli F, De Antoni L, Beccari T, Dundar M, Bertelli M. Bacteriophages presence in nature and their role in the natural selection of bacterial populations. Acta Biomed. 2020 Nov 9;91(13-S):e2020024.
  113. Deng Y, Jiang S, Duan H, Shao H, Duan Y. Bacteriophages and their potential for treatment of metabolic diseases. J Diabetes. 2024 Nov;16(11):e70024.
  114. Liang G, Bushman FD. The human virome: assembly, composition and host interactions. Nat Rev Microbiol. 2021 Aug;19(8):514-527.
  115. Ye J, Meng Q, Jin K, Luo Y, Yue T. Phage cocktail alleviated type 2 diabetes by reshaping gut microbiota and decreasing proinflammatory cytokines. Appl Microbiol Biotechnol. 2024 Dec;108(1):9.
  116. Saggar S, Mir PA, Kumar N et al. Traditional and herbal medicines: opportunities and challenges. Pharmacognosy Research, 2022, 14(2).
  117. Xu X, Yi H, Wu J, Kuang T, Zhang J, Li Q, Du H, Xu T, Jiang G, Fan G. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence. Biomed Pharmacother. 2021 Jan;133:110984.
  118. Song D, Hao J, Fan D. Biological properties and clinical applications of berberine. Front Med. 2020 ;14:564–82.
  119. Yang S, Li D, Yu Z, Li Y, Wu M. Multi-pharmacology of berberine in atherosclerosis and metabolic diseases: potential contribution of gut microbiota. Front Pharmacol. 2021; 12:709629.
  120. Wang H, Zhang H, Gao Z, Zhang Q, Gu C. The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Front Cell Infect Microbiol. 2022; 12:854885. 121.
  121. Fang X, Wu H, Wang X, Lian F, Li M, Miao R, Wei J, Tian J. Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism. Front Pharmacol. 2022 Jun 3;13:870407.
  122. Yao Y, Chen H, Yan L, Wang W, Wang D. Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids. Biomed Pharmacother. 2020; 131:110669.
  123. Yang F, Gao R, Luo X, Liu R, Xiong D. Berberine influences multiple diseases by modifying gut microbiota. Front Nutr. 2023 Aug 3;10:1187718.
  124. Ming J, Yu X, Xu X, Wang L, Ding C, Wang Z, Xie X, Li S, Yang W, Luo S, He Q, Du Y, Tian Z, Gao X, Ma K, Fang Y, Li C, Zhao J, Wang X, Ji Q. Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. Genome Med. 2021 Aug 9;13(1):125.
  125. Zhao JD, Li Y, Sun M, Yu CJ, Li JY, Wang SH, Yang D, Guo CL, Du X, Zhang WJ, Cheng RD, Diao XC, Fang ZH. Effect of berberine on hyperglycaemia and gut microbiota composition in type 2 diabetic Goto-Kakizaki rats. World J Gastroenterol. 2021 Feb 28;27(8):708-724.
  126. Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017 Sep 2;57(13):2889-2895.
  127. Wang J, Ghosh SS, Ghosh S. Curcumin improves intestinal barrier function: modulation of intracellular signaling, and organization of tight junctions. Am J Physiol Cell Physiol. 2017 Apr 1;312(4):C438-C445.
  128. Servida S, Piontini A, Gori F, Tomaino L, Moroncini G, De Gennaro Colonna V, La Vecchia C, Vigna L. Curcumin and Gut Microbiota: A Narrative Overview with Focus on Glycemic Control. Int J Mol Sci. 2024 Jul 14;25(14):7710.
  129. Lamichhane G, Olawale F, Liu J, Lee DY, Lee SJ, Chaffin N, Alake S, Lucas EA, Zhang G, Egan JM, Kim Y. Curcumin Mitigates Gut Dysbiosis and Enhances Gut Barrier Function to Alleviate Metabolic Dysfunction in Obese, Aged Mice. Biology (Basel). 2024 Nov 21;13(12):955.
  130. Huang J, Guan B, Lin L, Wang Y. Improvement of intestinal barrier function, gut microbiota, and metabolic endotoxemia in type 2 diabetes rats by curcumin. Bioengineered. 2021 Dec;12(2):11947-11958.